ストックスクリーナーアプリを入手
183.60
2.82%
-5.33
プレマーケット:
184.43
0.83
+0.45%
Astrazeneca Plc (AZN) 最新ニュース
AstraZeneca Data BreachLAPSUS$ Group Allegedly Claims Access to Internal Data - CyberSecurityNews
AstraZeneca PLC stock faces March pressure amid 100% YTD surge on NYSE - AD HOC NEWS
Signet Financial Management LLC Invests $2.57 Million in Astrazeneca Plc $AZN - MarketBeat
Morgan Stanley sees double-digit EPS growth for AstraZeneca PLC (AZN) - MSN
AstraZeneca plc stock faces pressure amid monthly declines but shows YTD strength in volatile pharma - AD HOC NEWS
Patterns Watch: Whats the outlook for AstraZeneca PLC Depositary Receipts sectorRecession Risk & Daily Entry Point Trade Alerts - baoquankhu1.vn
AstraZeneca PLC (AZN) gains after successful Saphnelo trial - MSN
Hilltop National Bank Purchases 7,586 Shares of Astrazeneca Plc $AZN - MarketBeat
QP Wealth Management LLC Buys New Position in Astrazeneca Plc $AZN - MarketBeat
Astrazeneca (AZN) Dips More Than Broader Market: What You Should Know - Yahoo Finance
Hacker Group LAPSUS$ Claims Alleged AstraZeneca Data Breach - Hackread
Form 6K AstraZeneca PLC ADR For: 20 March By Investing.com - Investing.com South Africa
AstraZeneca’s Pan-HER2 China Study Builds a Quiet Long-Term Edge in Oncology - TipRanks
AstraZeneca admits 45,750 new shares to London Stock Exchange main market - Investing.com
AstraZeneca (AZN) admits 45,750 new employee scheme shares to LSE - Stock Titan
Park National Corp OH Has $12.82 Million Stock Position in Astrazeneca Plc $AZN - MarketBeat
Miller Global Investments LLC Buys Shares of 7,716 Astrazeneca Plc $AZN - MarketBeat
2 Healthcare Stocks to Buy Before They Get Bought Out - The Motley Fool
Astrazeneca (NYSE:AZN) Rating Increased to Buy at Wall Street Zen - MarketBeat
AstraZeneca PLC stock faces pressure on NYSE amid insider filings and China expansion news - AD HOC NEWS
Moody's Changes Outlook on AstraZeneca to Positive on Organic Track Record - marketscreener.com
AstraZeneca (AZN) officer Mani Sharma details share and award holdings - Stock Titan
AstraZeneca Expands Real-World Push With New China Kidney Registry - TipRanks
AstraZeneca’s REVIVE Trial Targets Relapse After Osimertinib, Extending the Lung Cancer Playbook - TipRanks
AstraZeneca to boost cell therapy capabilities with new China investment - BioPharma Dive
Wilmington Savings Fund Society FSB Cuts Stock Position in Astrazeneca Plc $AZN - MarketBeat
Hudson Bay Capital Management LP Acquires 128,256 Shares of Astrazeneca Plc $AZN - MarketBeat
AstraZeneca to build cell therapy base, innovation centre in Shanghai - marketscreener.com
AstraZeneca Makes Soliris Available In Malaysia For Rare Disease Treatment - bernama
Cowen Maintains AZN AstraZeneca PLC at Buy on March 18, 2026 - Meyka
AstraZeneca: The $6 Billion Imfinzi Story Is Expanding Beyond Lung Cancer - Smartkarma
Why AstraZeneca Stock Was a Winner Today - MSN
AstraZeneca (AZN) Price Target Backed by Goldman After Baxdrostat Phase 3 Data - MSN
Challenges for AstraZeneca (AZN) Amid Drug Pricing Claims - GuruFocus
AZN Stock Quote Price and Forecast - CNN
Why AstraZeneca PLC (AZN) is one of the best immunotherapy stocks to buy according to hedge funds - MSN
Astrazeneca Plc $AZN Shares Sold by CIBC Private Wealth Group LLC - MarketBeat
AstraZeneca PLC (LON:AZN) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
AstraZeneca Advances Primary Care Lung Diagnosis Study With Global Reach - TipRanks
AstraZeneca's Imfinzi Secures Approval for Gastric Cancer in the EU - Yahoo Finance
Imfinzi EU Approval Expands AstraZeneca Gastric Cancer Reach For Investors - Yahoo Finance
AstraZeneca strikes up to $18.5B obesity drug deal with China’s CSPC Pharmaceutical - MSN
Sentiment Recap: Why is AstraZeneca PLC Depositary Receipt stock going up2026 Market Trends & Fast Gain Swing Alerts - baoquankhu1.vn
AstraZeneca (AZN) Faces Potential Impact from Recent Federal Rul - GuruFocus
Andrew Hamilton Acquires Omeprazole.com From AstraZeneca, Expanding Strategic Pharmaceutical Domain Portfolio - Yahoo Finance
Can AstraZeneca PLC Depositary Receipt expand into new marketsTrend Reversal & Real-Time Stock Entry Alerts - baoquankhu1.vn
Guggenheim Lifts PT on AstraZeneca PLC (AZN) to 16,000 GBp From 15,500 GBp - Insider Monkey
AstraZeneca receives EU approval for Imfinzi in early gastric cancer By Investing.com - Investing.com South Africa
AstraZeneca's Imfinzi Gets Expanded EU Label With Approval for Gastric Cancer -- Update - marketscreener.com
EU backs AstraZeneca (NYSE: AZN) Imfinzi for early gastric and GEJ cancers - Stock Titan
AstraZeneca (AZN) Gains EU Approval for Imfinzi in Cancer Treatm - GuruFocus
AstraZeneca PLC Stock (ISIN: US6549022043) Gains Momentum on EU Imfinzi Approval for Gastric Cancer - AD HOC NEWS
EU Approves AstraZeneca's Imfinzi Combo as First Perioperative Treatment for Early Gastric Cancer - marketscreener.com
Holocene Advisors LP Acquires 1,807,565 Shares of Astrazeneca Plc $AZN - MarketBeat
Fayez Sarofim & Co Has $298.78 Million Position in Astrazeneca Plc $AZN - MarketBeat
Astrazeneca's Imfinzi receives EU approval - Sharecast.com
Centiva Capital LP Takes Position in Astrazeneca Plc $AZN - MarketBeat
Capitolis Liquid Global Markets LLC Purchases New Stake in Astrazeneca Plc $AZN - MarketBeat
Astrazeneca Plc $AZN Shares Purchased by Bamco Inc. NY - MarketBeat
Bank of America Corp DE Boosts Holdings in Astrazeneca Plc $AZN - MarketBeat
ASTRAZENECA : Berenberg keeps its Buy rating - marketscreener.com
EU Approves AstraZeneca’s Imfinzi With FLOT Chemotherapy For Early Gastric Cancer - DirectorsTalk Interviews
Ameriprise Financial Inc. Boosts Stock Position in Astrazeneca Plc $AZN - MarketBeat
AstraZeneca's Imfinzi Combo Receives EU Approval for Early Gastric Cancer - marketscreener.com
Form 6K AstraZeneca PLC ADR For: 16 March - Investing.com
Imfinzi approved in the EU as first and only perioperative immunotherapy for patients with early gastric and gastroesophageal cancers - AstraZeneca
AstraZeneca PLC Stock (ISIN: US6549022043) Faces Valuation Scrutiny Amid Strong Oncology Momentum - AD HOC NEWS
AstraZeneca Abivax Talks Highlight Biotech Expansion And Valuation Upside Potential - Yahoo Finance
0.02%
大文字化:
|
ボリューム (24 時間):